Seres Therapeutics Inc (NASDAQ:MCRB) Announces New "Poop Pill" Phase 2 Study

Seres Therapeutics Inc (NASDAQ:MCRB) Announces New

(NASDAQ:MCRB) a near short term price target of $14.75.

Working capital declines Seres Therapeutics Inc. has witnessed a decline in the working capital over the previous year.

"We are pleased to have received highly constructive guidance from the FDA regarding further SER-109 clinical development and we plan to initiate a new clinical study as soon as possible", said Roger J. Pomerantz, M.D., President, CEO and Chairman of Seres.

Average Revenue Estimate of the company for the current Fiscal Quarter is $2.87 Billion, according to consensus of 11 analysts.

In the last quarter, Seres Therapeutics, Inc. reported Annual Earnings of $-0.46.

Seres Therapeutics will launch a new Phase 2 clinical trial for SER-109, an oral capsule being developed for patients with multiply recurrent Clostridium Difficile (C. Diff) infections. The fourth quarter net loss figure was inclusive of $3.0 million in revenue recognized associated with the company's collaboration with Nestlé Health Science. R&D expenses for the fourth quarter of 2016 were $20.3 million, as compared to $13.9 million for the same period in 2015.

Seres has amassed a library of bacteria from the human microbiome to use as a drugmaking platform in an effort to develop a class of "healthy gut" drugs to treat infections and metabolic disorders. Finally, Cowen and Company restated a "buy" rating on shares of Seres Therapeutics in a research report on Wednesday, February 1st. Current price places the company's stock -15.51% away from its 200-day simple moving average, 28.92%, away from the 50-day average and also 34.04% away from 20-day average. However, the stock is trading at -66.54% versus recent highs ($35.98). Among specific equities in focus are drug stocks Patheon NV (NYSE:PTHN) and Seres Therapeutics Inc (NASDAQ:MCRB), as well as casino concern Wynn Resorts, Limited (NASDAQ:WYNN). They issued an "overweight" rating and a $16.00 price target for the company. Zacks Investment Research lowered shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Wednesday, January 11th.

Agile Therapeutics, Inc. (AGRX) opened the session with a $2.36 price tag, later ranging from $2.34 to $2.88, the range at which the stock has traded at throughout the day.

Revenues for the year were $21.77 million. Now 12.9% of the stock's total float is wrapped up in these bearish bets, representing roughly four weeks' worth of buying power, at MCRB's average daily pace.

When we look at the Analyst Recommendations of the stock, the company has 1.91 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.

The company's ATR (Average True Range) is 0.92. Leading up to this report, we have seen a 21.01% rise in the stock price over the last 30 days and a 33.93% increase over the past 3 months. Seres Therapeutics Inc (NASDAQ:MCRB)'s price to free cash flow for trailing twelve months is 3.51. Artal Group S.A. now owns 700,000 shares of the company's stock worth $6,930,000 after buying an additional 200,000 shares during the last quarter. The company now has a Return on Equity of -48.00%.